A case of Behcets disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

Modern Rheumatology, 07/20/2011

Hirano T et al. – This treatment suppressed the patient’s clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behcet’s disease.

  • A 47–year–old female patient with Behcet’s disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab.
  • Because she relapsed, however, treatment with tocilizumab, a humanized anti–interleukin 6 receptor antibody, was started.

Print Article Summary Cat 2 CME Report